Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer

Tumor Biology

Volumn 36, Issue 10, 2015, Pages 7649-7658

  Guo, Ting ^a   Chen, Tao ^b   Gu, Chao ^a   Li, Bin ^a   Xu, Congjian ^a  

^a FUDAN UNIVERSITY   (China)

^b HARVARD UNIVERSITY   (United States)

Author keywords

CDKN1B; Cell cycle; G6PC; Glucose metabolism; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENZYME INHIBITOR; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; CDKN1B PROTEIN, HUMAN; CELL CYCLE PROTEIN; GLUCOSE;

ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL CYCLE REGULATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG INHIBITION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC ANALYSIS; GLUCOSE METABOLISM; GLYCOGEN ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TUMOR INVASION; WESTERN BLOTTING; CELL CYCLE CHECKPOINT; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

CATALYTIC DOMAIN; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GLUCOSE; GLUCOSE-6-PHOSPHATASE; HUMANS; OVARIAN NEOPLASMS; PHOSPHORYLATION;

EID: 84944275594     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3463-6     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41–4.
3. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27:2686–91.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.
5. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.
6. Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer. 2014;14:263–76.
7. Li B, Qiu B, Lee DS, Walton ZE, Ochocki JD, et al. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. Nature. 2014;513(7517):251–5.
8. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43–9.
9. Lei KJ, Shelly LL, Pan CJ, Sidbury JB, Chou JY. Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a. Science. 1993;262:580–3.
10. Abbadi S, Rodarte JJ, Abutaleb A, Lavell E, Smith CL, et al. Glucose-6-phosphatase is a key metabolic regulator of glioblastoma invasion. Mol Cancer Res. 2014;12(11):1547–59.
11. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.
12. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.
13. Madsen P, Lundbeck JM, Jakobsen P, Varming AR, Westergaard N. Glucose-6-phosphatase catalytic enzyme inhibitors: synthesis and in vitro evaluation of novel 4,5,6,7-tetrahydrothieno[3,2-c]- and -[2,3-c]pyridines. Bioorg Med Chem. 2000;8:2277–89.
14. Westergaard N, Madsen P, Lundbeck JM, Jakobsen P, Varming A, et al. Identification of two novel and potent competitive inhibitors of the glucose-6-phosphatase catalytic protein. Diabetes Obes Metab. 2002;4:96–105.
15. Gu C, Zhang Z, Yu Y, Liu Y, Zhao F, et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci. 2011;102:557–64.
16. Feng C-C, Guan M, Wang P-H, Ding Q, Zhang Y-F, et al. Pigment epithelium-derived factor inhibits T24 bladder cancer cell growth in vitro and in vivo. Rom Biotechnol Lett. 2011;16:5829–40.
17. Majumdar S, Farris CL, Kabat BE, Jung DO, Ellsworth BS. Forkhead Box O1 is present in quiescent pituitary cells during development and is increased in the absence of p27 Kip1. PLoS One. 2012;7, e52136.
18. Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013;19:1381–8.
19. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30:3402–7.
20. Hsu FH, Serpedin E, Hsiao TH, Bishop AJ, Dougherty ER, et al. Reducing confounding and suppression effects in TCGA data: an integrated analysis of chemotherapy response in ovarian cancer. BMC Genomics. 2012;13 Suppl 6:S13.
21. Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, et al. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One. 2013;8, e54873.
22. Han Y, Huang H, Xiao Z, Zhang W, Cao Y, et al. Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS One. 2012;7, e52745.
23. Zhang W, Ota T, Shridhar V, Chien J, Wu B, et al. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment. PLoS Comput Biol. 2013;9, e1002975.
24. Kang HJ, Chun SM, Kim KR, Sohn I, Sung CO. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One. 2013;8, e72609.
25. Ying H, Lv J, Ying T, Jin S, Shao J, et al. Gene-gene interaction network analysis of ovarian cancer using TCGA data. J Ovarian Res. 2013;6:88.
26. Hu ZY, Xiao L, Bode AM, Dong Z, Cao Y. Glycolytic genes in cancer cells are more than glucose metabolic regulators. J Mol Med (Berl). 2014;92:837–45.
27. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88.
28. Costa-Guda J, Soong CP, Parekh VI, Agarwal SK, Arnold A. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas. Horm Cancer. 2013;4:301–7.
29. Sangwan M, McCurdy SR, Livne-Bar I, Ahmad M, Wrana JL, et al. Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation. Oncogene. 2012;31:5019–28.